Navigation Links
Martek to Present at Upcoming Citi Small / Mid Cap Conference
Date:11/3/2010

COLUMBIA, Md., Nov. 3, 2010 /PRNewswire-FirstCall/ -- Martek Biosciences Corporation (Nasdaq: MATK) announced today that it will be presenting at the 2010 Citi Small / Mid Cap Conference being held on November 16-17, 2010 in Las Vegas, NV.  Steve Dubin, Chief Executive Officer is scheduled to present on Tuesday, November 16 at 10:15 a.m. Pacific Time (1:15 p.m. Eastern Time).  A live audio webcast of the presentation can be accessed at: http://www.veracast.com/webcasts/citigroup/smidcap2010/42104135.cfm

Martek Biosciences Corporation (Nasdaq: MATK) is a leader in the innovation, development, production and sales of high-value products from microbial sources that promote health and wellness through nutrition. The company's technology platform consists of its core expertise, broad experience and proprietary technology in areas such as microbial biology, algal genomics, fermentation and oil processing. This technology platform has resulted in Martek's development of a number of products including the company's flagship product, life'sDHA(TM), a sustainable and vegetarian source of algal DHA (docosahexaenoic acid) important for brain, heart and eye health throughout life for use in infant formula, pregnancy and nursing products, foods and beverages and dietary supplements. The company also produces life'sARA(TM) (arachidonic acid), an omega-6 fatty acid, for use in infant formula and growing-up milks. Martek's subsidiary, Amerifit Brands, develops, markets and distributes branded consumer health and wellness products and holds leading brand positions in all of its key product categories. Amerifit products are sold in most major mass, club, drug, grocery and specialty stores and include: Culturelle(R), a leading probiotic supplement; AZO, the leading OTC brand addressing symptom relief, detection and prevention of urinary tract infections; and ESTROVEN(R), the leading all-natural nutritional supplement brand addressing the symptoms of menopause. Martek currently has a number of nutritional health and wellness products under development that it plans to commercialize and distribute through Amerifit's distribution channels.

Martek's technology platform has also made it a sought-after partner on a range of groundbreaking projects in process, including the development of microbially-derived biofuels and the development of DHA-containing oilseeds. For more information on Martek Biosciences, visit http://www.martek.com/. For a complete list of life'sDHA and life'sARA products, visit http://www.lifesdha.com/. For more information about Amerifit Brands, visit www.amerifit.com.

Sections of this release contain forward-looking statements. These statements are based upon numerous assumptions which Martek cannot control and involve risks and uncertainties that could cause actual results to differ. These statements should be understood in light of the risk factors set forth in the company's filings with the Securities and Exchange Commission, including, but not limited to, the company's Form 10-K for the fiscal year ended October 31, 2009 and other filed reports on Form 10-K, Form 10-K/A, Form 10-Q and Form 8-K.Contact:Kyle StultsInvestor Relations(410) 740-0081investors@martek.com
'/>"/>

SOURCE Martek Biosciences Corporation
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Martek to Present at Upcoming UBS Conference
2. Martek Announces Third Quarter FY 2010 Financial Results
3. Martek Announces Fourth Quarter and FY 2009 Financial Results
4. Martek Signs Sole-Source Supply Agreement with Fonterra
5. Martek to Announce Fourth Quarter and Fiscal Year 2009 Results
6. Martek Announces Addition to Its Board of Directors
7. Martek to Present at Two Upcoming Investor Conferences
8. Martek Announces Settlement of Patent Dispute with Capsugel France
9. Federal Circuit Rules in Marteks Favor in Appeal of Patent Infringement Case
10. Martek Signs Sole-Source Supply Agreement with Milk Powder Solutions
11. Martek to Announce Third Quarter 2009 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/5/2016)... 5, 2016  Eisai Inc. announced today final ... of rufinamide, which were presented at the 2016 ... held from December 2-6 in Houston, ... tolerability and cognitive data showed that patients who ... and tolerability profiles, cognitive development and behavior, compared ...
(Date:12/4/2016)... SAN DIEGO , Dec. 3, 2016  In ... Society of Hematology (ASH) Annual Meeting and Exposition in ... advanced biomedical engineering methods to improve the delivery of ... conditions. These new methods are designed to carry therapies ... are needed most, which could provide a substantial advantage ...
(Date:12/2/2016)... Calif. , Dec. 2, 2016 Amgen (NASDAQ: ... AGN ) today announced the submission of a Marketing Authorization ... 215, a biosimilar candidate to Avastin ® (bevacizumab). The ... submitted to the EMA. "The submission of ... Amgen seeks to expand our oncology portfolio," said Sean ...
(Date:12/2/2016)... (PRWEB) , ... December 01, 2016 , ... ... pneumatic tube systems for North American hospitals, will present its chain-of-custody solution for ... and Exhibition in Las Vegas, Nev., Dec. 4-8, 2016. , Aerocom has a ...
Breaking Biology Technology:
(Date:11/17/2016)... Global Market Watch: Primarily supported by ... Banks and Academics) market is to witness a value of ... the highest Compounded Annual Growth Rate (CAGR) of 10.75% is ... analysis period 2014-2020. North America is ... Europe at 9.56% respectively. Report ...
(Date:11/16/2016)... Nov. 16, 2016 Sensory Inc ., ... security for consumer electronics, and VeriTran , ... retail industry, today announced a global partnership that ... to authenticate users of mobile banking and mobile ... software which requires no specialized biometric scanners, ...
(Date:11/15/2016)... DUBLIN , Nov 15, 2016 Research ... - Global Forecast to 2021" report to their offering. ... ... reach USD 16.18 Billion by 2021 from USD 6.21 Billion in ... Growth of the bioinformatics market is driven by ...
Breaking Biology News(10 mins):